NMDA and non-NMDA receptor antagonists inhibit photic induction of Fos protein in the hamster suprachiasmatic nucleus

Brain Res Bull. 1992 May;28(5):831-5. doi: 10.1016/0361-9230(92)90269-4.

Abstract

We previously reported that systemic treatment with a noncompetitive antagonist affecting the NMDA subtype of excitatory amino acid (EAA) receptor, MK-801, inhibits photic induction of Fos-like immunoreactivity (Fos-lir) in the hamster suprachiasmatic nucleus (SCN). Because MK-801 blocks the Ca2+ channel associated with the NMDA receptor, it may also influence the activity of other transmitters acting through Ca2+ channels. To assess the specificity of these effects, we compared the effects on photic induction of Fos-lir of several treatments: central injection of a competitive NMDA antagonist, CPP; central injection of a non-NMDA antagonist, DNQX; and systemic injection of the non-competitive NMDA antagonist, ketamine. Fos-lir was induced in SCN cells of vehicle-injected hamsters exposed to a light pulse 4-5 h after dark onset. Pretreatment with CPP (greater than 2 nmoles) or ketamine (greater than 100 mg/kg) caused a dose-related inhibition of photic induction of Fos-lir in portions of the SCN. These treatments reduced Fos-lir mainly in the rostral SCN and ventrolateral, but not dorsolateral, portions of the caudal SCN. Pretreatment with DNQX (greater than 20 nmoles) also inhibited photic induction of Fos-lir in the same regions of the SCN. These results indicate that photic induction of Fos protein in a portion of the hamster SCN is regulated by both NMDA and non-NMDA types of EAA receptor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Cricetinae
  • Evoked Potentials / drug effects
  • Ketamine / pharmacology
  • Male
  • Mesocricetus
  • Oncogene Proteins v-fos / biosynthesis*
  • Optic Nerve / physiology
  • Photic Stimulation
  • Piperazines / pharmacology
  • Quinoxalines / pharmacology
  • Receptors, Amino Acid
  • Receptors, Cell Surface / drug effects
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*
  • Suprachiasmatic Nucleus / drug effects
  • Suprachiasmatic Nucleus / metabolism*

Substances

  • Oncogene Proteins v-fos
  • Piperazines
  • Quinoxalines
  • Receptors, Amino Acid
  • Receptors, Cell Surface
  • Receptors, N-Methyl-D-Aspartate
  • FG 9041
  • Ketamine
  • 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid